Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 0.22
IPXL's Cash-to-Debt is ranked lower than
85% of the 719 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.89 vs. IPXL: 0.22 )
Ranked among companies with meaningful Cash-to-Debt only.
IPXL' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.22  Med: 4.95 Max: No Debt
Current: 0.22
Equity-to-Asset 0.34
IPXL's Equity-to-Asset is ranked lower than
83% of the 660 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.62 vs. IPXL: 0.34 )
Ranked among companies with meaningful Equity-to-Asset only.
IPXL' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.12  Med: 0.49 Max: 0.82
Current: 0.34
0.12
0.82
Piotroski F-Score: 3
Altman Z-Score: 0.10
Beneish M-Score: -5.84
WACC vs ROIC
8.08%
-34.04%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % -59.94
IPXL's Operating Margin % is ranked lower than
85% of the 672 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.86 vs. IPXL: -59.94 )
Ranked among companies with meaningful Operating Margin % only.
IPXL' s Operating Margin % Range Over the Past 10 Years
Min: -59.94  Med: 14.59 Max: 44.72
Current: -59.94
-59.94
44.72
Net Margin % -57.26
IPXL's Net Margin % is ranked lower than
85% of the 673 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.73 vs. IPXL: -57.26 )
Ranked among companies with meaningful Net Margin % only.
IPXL' s Net Margin % Range Over the Past 10 Years
Min: -57.26  Med: 11.2 Max: 46
Current: -57.26
-57.26
46
ROE % -49.87
IPXL's ROE % is ranked lower than
87% of the 690 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.66 vs. IPXL: -49.87 )
Ranked among companies with meaningful ROE % only.
IPXL' s ROE % Range Over the Past 10 Years
Min: -55.98  Med: 12.27 Max: 125.75
Current: -49.87
-55.98
125.75
ROA % -24.58
IPXL's ROA % is ranked lower than
82% of the 721 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.48 vs. IPXL: -24.58 )
Ranked among companies with meaningful ROA % only.
IPXL' s ROA % Range Over the Past 10 Years
Min: -25.21  Med: 7.63 Max: 38.8
Current: -24.58
-25.21
38.8
ROC (Joel Greenblatt) % -149.95
IPXL's ROC (Joel Greenblatt) % is ranked lower than
84% of the 710 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.44 vs. IPXL: -149.95 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
IPXL' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -149.95  Med: 40.77 Max: 236.29
Current: -149.95
-149.95
236.29
3-Year Revenue Growth Rate 15.90
IPXL's 3-Year Revenue Growth Rate is ranked higher than
76% of the 600 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.00 vs. IPXL: 15.90 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
IPXL' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 30.1 Max: 204.1
Current: 15.9
0
204.1
GuruFocus has detected 3 Warning Signs with Impax Laboratories Inc $IPXL.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» IPXL's 10-Y Financials

Financials (Next Earnings Date: 2017-06-01 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

IPXL Guru Trades in Q1 2016

Joel Greenblatt 478,620 sh (+2317.15%)
Jim Simons 117,700 sh (+40.45%)
Paul Tudor Jones 28,203 sh (+28.41%)
Eaton Vance Worldwide Health Sciences Fund 773,500 sh (unchged)
NWQ Managers 190,660 sh (-3.89%)
Alan Fournier 2,083,074 sh (-10.27%)
» More
Q2 2016

IPXL Guru Trades in Q2 2016

Paul Tudor Jones 52,408 sh (+85.82%)
Joel Greenblatt 733,848 sh (+53.33%)
Jim Simons Sold Out
Eaton Vance Worldwide Health Sciences Fund Sold Out
NWQ Managers 186,406 sh (-2.23%)
Alan Fournier 1,949,569 sh (-6.41%)
» More
Q3 2016

IPXL Guru Trades in Q3 2016

Jim Simons 177,700 sh (New)
Steven Cohen 566,500 sh (New)
NWQ Managers 1,068,795 sh (+473.37%)
Alan Fournier Sold Out
Joel Greenblatt Sold Out
Paul Tudor Jones 16,230 sh (-69.03%)
» More
Q4 2016

IPXL Guru Trades in Q4 2016

Jim Simons 1,093,002 sh (+515.08%)
Paul Tudor Jones 77,612 sh (+378.20%)
Steven Cohen 581,400 sh (+2.63%)
NWQ Managers 1,026,237 sh (-3.98%)
» More
» Details

Insider Trades

Latest Guru Trades with IPXL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:OTCPK:LPCUF, NAS:AMPH, NAS:HRTX, NYSE:LCI, OTCPK:NPPNY, OTCPK:APHQF, NAS:SCLN, NAS:FLXN, OTCPK:TZHGF, NAS:SCMP, OTCPK:ACBFF, NAS:LBIO, NAS:ACET, NAS:DEPO, NAS:KPTI, OTCPK:TWMJF, NAS:INNL, NAS:MNTA, NAS:ADMS, NAS:RIGL » details
Traded in other countries:ILR.Germany,
Impax Laboratories Inc is a technology-based, specialty pharmaceutical company. It is engaged in the development and commercialization of bioequivalent and brand-name pharmaceuticals, utilizing its controlled-release and other in-house development.

Impax Laboratories makes generic drugs, specializing in controlled-release formulations of brand-name pharmaceuticals. Impax was formed through a recapitalization in 1999, with privately held Impax Pharmaceuticals merging into Global Pharmaceutical Corporation. Based in Hayward, Calif., the company employs about 750 people in 12 facilities in the United States and one under construction in Taiwan.

Ratios

vs
industry
vs
history
Forward PE Ratio 13.21
IPXL's Forward PE Ratio is ranked higher than
61% of the 89 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.46 vs. IPXL: 13.21 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PB Ratio 1.09
IPXL's PB Ratio is ranked higher than
86% of the 761 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.93 vs. IPXL: 1.09 )
Ranked among companies with meaningful PB Ratio only.
IPXL' s PB Ratio Range Over the Past 10 Years
Min: 0.94  Med: 2.36 Max: 4.3
Current: 1.09
0.94
4.3
PS Ratio 0.80
IPXL's PS Ratio is ranked higher than
86% of the 727 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.85 vs. IPXL: 0.80 )
Ranked among companies with meaningful PS Ratio only.
IPXL' s PS Ratio Range Over the Past 10 Years
Min: 0.69  Med: 2.51 Max: 5.73
Current: 0.8
0.69
5.73
Price-to-Free-Cash-Flow 29.94
IPXL's Price-to-Free-Cash-Flow is ranked lower than
58% of the 228 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 24.42 vs. IPXL: 29.94 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
IPXL' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 2.06  Med: 18.36 Max: 103.25
Current: 29.94
2.06
103.25
Price-to-Operating-Cash-Flow 8.79
IPXL's Price-to-Operating-Cash-Flow is ranked higher than
79% of the 290 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.18 vs. IPXL: 8.79 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
IPXL' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 1.84  Med: 13.67 Max: 4004
Current: 8.79
1.84
4004
Shiller PE Ratio 14.35
IPXL's Shiller PE Ratio is ranked higher than
93% of the 159 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 44.64 vs. IPXL: 14.35 )
Ranked among companies with meaningful Shiller PE Ratio only.
IPXL' s Shiller PE Ratio Range Over the Past 10 Years
Min: 12.5  Med: 26.61 Max: 506.2
Current: 14.35
12.5
506.2
Current Ratio 1.96
IPXL's Current Ratio is ranked lower than
56% of the 614 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.31 vs. IPXL: 1.96 )
Ranked among companies with meaningful Current Ratio only.
IPXL' s Current Ratio Range Over the Past 10 Years
Min: 0.34  Med: 3.08 Max: 5.64
Current: 1.96
0.34
5.64
Quick Ratio 1.42
IPXL's Quick Ratio is ranked lower than
61% of the 613 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.73 vs. IPXL: 1.42 )
Ranked among companies with meaningful Quick Ratio only.
IPXL' s Quick Ratio Range Over the Past 10 Years
Min: 0.34  Med: 2.64 Max: 5.19
Current: 1.42
0.34
5.19
Days Inventory 56.12
IPXL's Days Inventory is ranked higher than
82% of the 626 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 115.23 vs. IPXL: 56.12 )
Ranked among companies with meaningful Days Inventory only.
IPXL' s Days Inventory Range Over the Past 10 Years
Min: 50.25  Med: 87.54 Max: 118.81
Current: 56.12
50.25
118.81
Days Sales Outstanding 113.94
IPXL's Days Sales Outstanding is ranked lower than
76% of the 571 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 77.23 vs. IPXL: 113.94 )
Ranked among companies with meaningful Days Sales Outstanding only.
IPXL' s Days Sales Outstanding Range Over the Past 10 Years
Min: 34.05  Med: 85.17 Max: 189.27
Current: 113.94
34.05
189.27
Days Payable 22.06
IPXL's Days Payable is ranked lower than
91% of the 522 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 73.13 vs. IPXL: 22.06 )
Ranked among companies with meaningful Days Payable only.
IPXL' s Days Payable Range Over the Past 10 Years
Min: 20.18  Med: 40.82 Max: 57.29
Current: 22.06
20.18
57.29

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -1.90
IPXL's 3-Year Average Share Buyback Ratio is ranked higher than
63% of the 441 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.00 vs. IPXL: -1.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
IPXL' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -86.4  Med: -5 Max: -1.7
Current: -1.9
-86.4
-1.7

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 0.75
IPXL's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
90% of the 314 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.37 vs. IPXL: 0.75 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
IPXL' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.75  Med: 1.12 Max: 3.37
Current: 0.75
0.75
3.37
Price-to-Median-PS-Value 0.32
IPXL's Price-to-Median-PS-Value is ranked higher than
95% of the 664 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.20 vs. IPXL: 0.32 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
IPXL' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.32  Med: 1.41 Max: 32.78
Current: 0.32
0.32
32.78
Earnings Yield (Greenblatt) % -40.16
IPXL's Earnings Yield (Greenblatt) % is ranked lower than
93% of the 788 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.86 vs. IPXL: -40.16 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
IPXL' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -40.16  Med: 9.3 Max: 56
Current: -40.16
-40.16
56
Forward Rate of Return (Yacktman) % 0.72
IPXL's Forward Rate of Return (Yacktman) % is ranked lower than
68% of the 364 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.76 vs. IPXL: 0.72 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
IPXL' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -21.4  Med: 2.8 Max: 90.2
Current: 0.72
-21.4
90.2

More Statistics

Revenue (TTM) (Mil) $824.4
EPS (TTM) $ -6.62
Beta1.15
Short Percentage of Float5.39%
52-Week Range $7.75 - 37.20
Shares Outstanding (Mil)73.75

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 832 885 913
EPS ($) 0.79 1.07 1.25
EPS without NRI ($) 0.79 1.07 1.25
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for IPXL

Headlines

Articles On GuruFocus.com
Teva: Good Value, Questionable Management? Jan 02 2017 
Integer Investments: Akorn Has 100% Upside Potential Jan 01 2017 
Sam Isaly Swaps 3 Health Care Stocks in Second Quarter Jul 29 2016 
Kyle Bass Sells Stakes in 11 Health Care Companies Mar 01 2016 
Alan Fournier Makes Modest Reductions in Middleby and Priceline Jan 12 2016 
Allergan Among Health Care Holdings in Alan Fournier's Portfolio Dec 15 2015 
Pharmaceutical Stocks Hold Prominent Positions in Kyle Bass' 3rd-Quarter Activity Nov 27 2015 
Kyle Bass Goes Fishing for These 3 New Holdings Nov 26 2015 
Alan Fournier's Highest Performing Stocks Jul 15 2015 
Alan Fournier's Most Heavily Weighted Trades In Q1 2015 May 28 2015 

More From Other Websites
Falling Earnings Estimates Signal Weakness Ahead for Impax Laboratories (IPXL) Mar 22 2017
Impax Hires Morgan Stanley for Strategic Review, Possible Sale Mar 08 2017
Impax Labs downgraded by Susquehanna Mar 08 2017
Impax Laboratories, Inc. :IPXL-US: Earnings Analysis: Q4, 2016 By the Numbers : March 7, 2017 Mar 07 2017
IMPAX LABORATORIES INC Financials Mar 07 2017
New Strong Sell Stocks for March 6th Mar 06 2017
Impax (IPXL) Q4 Earnings in Line, Revenues Miss Estimates Mar 02 2017
Impax Laboratories (IPXL) is Oversold: Can It Recover? Mar 02 2017
Lincoln National, Lowe's and Weight Watchers jump Mar 01 2017
Edited Transcript of IPXL earnings conference call or presentation 1-Mar-17 1:30pm GMT Mar 01 2017
Biotech Premarket Movers: Impax, Clearside Biomedical, Mylan Mar 01 2017
Q4 2016 Impax Laboratories Inc Earnings Release - Before Market Open Mar 01 2017
IMPAX LABORATORIES INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation... Mar 01 2017
Impax Labs reports 4Q loss Mar 01 2017
Impax Labs reports 4Q loss Mar 01 2017
Impax Reports Fourth Quarter and Full Year 2016 Financial Results Mar 01 2017
Mylan Generic EpiPen To Swipe Share From Impax, Kaleo: Analyst Feb 28 2017
Impax to Present at Upcoming Investor Conferences Feb 27 2017
Zacks.com featured highlights: Applied Materials, General Motors, Citizens Financial Group, Chicago... Feb 22 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)